Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17876670 | 0.94 | CYP2C9 (0.61) | CYP2C9CYP2C19CYP3A4ACE2MAPT | |
| SCHEMBL17876522 | 0.94 | CYP2C9 (0.53) | CYP2C9CYP2C19CYP3A4ACE2MAPT | |
| SCHEMBL17876698 | 0.94 | CYP2C9 (0.53) | CYP2C9CYP2C19CYP3A4ACE2MAPT | |
| SCHEMBL17876689 | 0.93 | CYP2C9 (0.60) | CYP2C9CYP2C19CYP3A4ACE2SMN1; SMN2 | |
| SCHEMBL12295455 | 0.92 | CYP2C9 (0.51) | CYP2C9CYP2C19CYP3A4ACE2 | |
| SCHEMBL17876533 | 0.91 | CYP2C9 (0.57) | CYP2C9CYP2C19CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL17876541 | 0.91 | CYP2C9 (0.58) | CYP2C9CYP2C19CYP3A4SCDEPHX2 | |
| SCHEMBL17876686 | 0.91 | CYP2C9 (0.67) | CYP2C9CYP2C19CYP3A4SMN1; SMN2EPHX2 | |
| SCHEMBL17876490 | 0.88 | CYP2C9 (0.57) | CYP2C9CYP2C19CYP3A4ITGA4ACE2 | |
| SCHEMBL23655952 | 0.88 | CYP2C9 (0.53) | CYP2C9CYP2C19CYP3A4ACE2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | CYP2C9 4235/4885CYP2C19 4181/4885CYP3A4 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.